An Australian diagnostic microbiology surge response to the COVID-19 pandemic.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
May 2021
Historique:
received: 10 11 2020
revised: 04 01 2021
accepted: 10 01 2021
pubmed: 25 1 2021
medline: 14 4 2021
entrez: 24 1 2021
Statut: ppublish

Résumé

Diagnostic microbiology services form a critical component of the response to infectious disease outbreaks. Like previous respiratory virus pandemics, the COVID-19 pandemic has placed significant strains on the standing capacity of laboratories around the world. In this case study, we describe the surge response required by our laboratory to meet the fluctuating demand for SARS-CoV-2 in our regional pathology service in Western Sydney, Australia between March and May 2020. While the overall number of SARS-CoV-2 PCR positive cases was relatively low compared to other Australian local health districts, testing numbers were highly unpredictable and changed on a weekly basis as local outbreaks were detected. As with other laboratories, numerous other challenges were also faced during this period, including the requirement to introduce a new and unaccredited diagnostic PCR assay for SARS-CoV-2, local and global shortages of reagents for sampling and sample processing, and a significant institutional SARS-CoV-2 outbreak in our laboratory catchment area. A successful service delivery during this period could only be maintained by a dynamic whole-of-laboratory and organizational response including (1) operational changes to the hours of service and the expansion of diagnostic testing at our laboratory site and other sites within our organization (2) careful management of specialist staff and re-training and recruitment of additional staff (3) changes to laboratory workflows to improve SARS-CoV-2 PCR test turnaround time and to accommodate limits to precious laboratory reagents; (4) clear communication within our laboratory and the NSW Health Pathology organization; and (5) collaborative co-ordination and support by NSW Health Pathology.

Identifiants

pubmed: 33486387
pii: S0732-8893(21)00002-X
doi: 10.1016/j.diagmicrobio.2021.115309
pmc: PMC7833915
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115309

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Commun Dis Intell (2018). 2020 Aug 26;44:
pubmed: 32847492
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
Front Cell Dev Biol. 2020 Jun 04;8:468
pubmed: 32582718
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Infect. 2020 Jun;80(6):e14-e18
pubmed: 32171866
Emerg Infect Dis. 2010 Jan;16(1):8-13
pubmed: 20031036
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Pathology. 2020 Dec;52(7):811-814
pubmed: 33250079
Viruses. 2020 Mar 27;12(4):
pubmed: 32230900

Auteurs

Rebecca Sparks (R)

Department of Microbiology and Infectious Diseases, NSW Health Pathology Nepean, Penrith, New South Wales, Australia.

Rifky Balgahom (R)

Department of Microbiology and Infectious Diseases, NSW Health Pathology Nepean, Penrith, New South Wales, Australia.

Catherine Janto (C)

Department of Microbiology and Infectious Diseases, NSW Health Pathology Nepean, Penrith, New South Wales, Australia.

Adam Polkinghorne (A)

Department of Microbiology and Infectious Diseases, NSW Health Pathology Nepean, Penrith, New South Wales, Australia; Nepean Clinical School, Faculty of Medicine and Health, University of Sydney, Kingswood, New South Wales, Australia.

James Branley (J)

Department of Microbiology and Infectious Diseases, NSW Health Pathology Nepean, Penrith, New South Wales, Australia; Nepean Clinical School, Faculty of Medicine and Health, University of Sydney, Kingswood, New South Wales, Australia.

Harsha Samarasekara (H)

Department of Microbiology and Infectious Diseases, NSW Health Pathology Nepean, Penrith, New South Wales, Australia. Electronic address: harsha.samarasekara@health.nsw.gov.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH